İlaç-Na ⁇ ve Parkinson Hastalığı Hastalarında Fonksiyonel Bağomikler ve Hastalık İlerlemesi.
Functional Connectomics and Disease Progression in Drug-Naïve Parkinson's Disease Patients.
DOI: 10.1002/mds.28541PMID: 33639029
“Parkinson progression” Aramayı temizle
Functional Connectomics and Disease Progression in Drug-Naïve Parkinson's Disease Patients.
DOI: 10.1002/mds.28541PMID: 33639029
Sleep problems affect quality of life in Parkinson's disease along disease progression.
DOI: 10.1016/j.sleep.2021.02.036PMID: 33756280
Facial tremor in patients with Parkinson's disease: prevalence, determinants and impacts on disease progression.
DOI: 10.1186/s12883-021-02105-yPMID: 33622288
Letter to the editor in response to the letter from the EPIPARK Study Group regarding the publication 'Progression of fatigue in Parkinson's disease - a 9-year follow-up' (Eur J Neurol 2021. doi:10.1111/ene.14520).
DOI: 10.1111/ene.14765PMID: 33547699
Cellular and molecular pathophysiology in the progression of Parkinson's disease.
DOI: 10.1007/s11011-021-00689-5PMID: 33599945
Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study.
DOI: 10.1016/j.parkreldis.2021.02.008PMID: 33639572
Association of <i>SNCA</i> Parkinson's Disease Risk Polymorphisms With Disease Progression in Newly Diagnosed Patients.
DOI: 10.3389/fneur.2020.620585PMID: 33643180
Cystic fibrosis transmembrane conductance regulator-associated ligand protects dopaminergic neurons by differentially regulating metabotropic glutamate receptor 5 in the progression of neurotoxin 6-hydroxydopamine-induced Parkinson's disease model.
DOI: 10.1016/j.neuro.2021.02.003PMID: 33571554
Robust Bayesian Analysis of Early-Stage Parkinson's Disease Progression Using DaTscan Images.
DOI: 10.1109/tmi.2020.3031478PMID: 33055025
Association of autonomic symptoms with cerebrospinal fluid biomarkers in Parkinson disease and scans without evidence of dopaminergic deficit.
DOI: 10.1097/md.0000000000024837PMID: 33607852
Motor Progression in Early-Stage Parkinson's Disease: A Clinical Prediction Model and the Role of Cerebrospinal Fluid Biomarkers.
DOI: 10.3389/fnagi.2020.627199PMID: 33568988
LncRNA XIST sponges miR-199a-3p to modulate the Sp1/LRRK2 signal pathway to accelerate Parkinson's disease progression.
DOI: 10.18632/aging.202378PMID: 33494069
Kayıtlar bilimsel kaynaklardan alınır. Bibliyografik kayıt sayısı, Türkçe çeviri veya editoryal onay sayısı değildir.